ArticleClinical rheumatology2015
Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab.
Article in Clinical rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- Anti-citrullinated Protein Antibody-positive Arthralgia Associated with an L110P-E148Q Double Heterozygote: A Case-based Review.Internal medicine (Tokyo, Japan) · 2026Review
- Tocilizumab-associated oral ulcerations: a case report and scoping review.Frontiers in medicine · 2026Review
- Treatment Options in Pediatric Behçet's Disease.Paediatric drugs · 2023Review
- New insights on multigenic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2022Review
- Neutrophilic Dermatoses: a Clinical Update.Current dermatology reports · 2022Review
- Biologic treatments in Behçet's disease.European journal of rheumatology · 2021Article
- Recent Insights into the Management of Behçet Syndrome.Journal of inflammation research · 2021Review
- Update on the Treatment of Behcet's Disease of the Small Bowel with Biologic Agents.Current gastroenterology reports · 2020Review
- Behçet's Disease in Children: Diagnostic and Management Challenges.Therapeutics and clinical risk management · 2020Review
- Update on the treatment of Behçet's syndrome.Internal and emergency medicine · 2019Review
- Treating the Different Phenotypes of Behçet's Syndrome.Frontiers in immunology · 2019Review
- Behcet's Disease With Cerebral Artery Infarction Caused by Cerebral Arteritis as an Early Symptom Only With Elevated Interleukin-8.Frontiers in neurology · 2019Article
- Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review.Rheumatology international · 2018Review
- Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.Clinical rheumatology · 2017Article
- IL-6 blockade in the management of non-infectious uveitis.Clinical rheumatology · 2017Review
- Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.International journal of rheumatology · 2017Review
- Update on the Medical Management of Gastrointestinal Behçet's Disease.Mediators of inflammation · 2017Review
- Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease.Medicine · 2015Observational
- Pathogenesis of Behçet's disease: autoinflammatory features and beyond.Seminars in immunopathology · 2015Review
- Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.Mediators of inflammation · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report on a patient with a long-standing history of recurrent oral aphthosis and pseudofolliculitis, diagnosed with Behçet's disease (BD), previously treated with high-dose prednisone, colchicine, cyclosporine, cyclophosphamide and methotrexate, all of which were partially effective. Treatment with the chimeric mouse-human anti-tumour necrosis factor (TNF)-α monoclonal antibody infliximab brought about the resolution of mucocutaneous lesions for a period of 6 years. After an oral and articular BD relapse, the anti-interleukin-6 agent tocilizumab was started in association with high-dose prednisone. Unexpectedly, the patient experienced a paradoxical mucocutaneous flare following tocilizumab administration, which worsened after the second infusion. Tocilizumab was then discontinued, and total recovery was achieved after the patient was started on the fully human anti-TNF-α monoclonal antibody golimumab in association with colchicine and methylprednisolone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.